Linsanity, for every patent granted, biotechs will have multiple patent applications that lapse, cease or are withdrawn – for a number of reasons.
What counts much more than lapsed, withdrawn and ceased patent applications (which happen for a number of reasons) is whether any patents are granted.
My list wasn’t well put together. Here’s another, this one showing 15 granted patents. Proof enough, I think, of valid IP.
Method of determining, identifying or isolating cell-penetrating peptidesWO EP US AU CA
AU2017201163B2 Katrin HOFFMAN Phylogica Limited
Priority 2011-05-23 • Filed 2017-02-21 • Granted 2018-07-05 • Published 2018-07-05
Abstract of the disclosure The present invention provides a method of determining or identifying or isolating a cell penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This …
Methods of constructing and screening libraries of peptide structuresWO EP US JP AU CA DK
US9567373B2 Paul Michael Watt Phylogica Limited
Priority 2006-02-20 • Filed 2013-09-26 • Granted 2017-02-14 • Published 2017-02-14
The present invention provides the means for producing libraries of peptide structures for drug screening applications that are capable of folding or assuming their native conformations independently of artificial scaffolds or flanking sequences in the proteins from which they are derived. The …
Methods of constructing and screening diverse expression librariesWO EP US AT CA DE
US7270969B2 Paul Michael Watt Phylogica Limited
Priority 1999-05-05 • Filed 2003-02-21 • Granted 2007-09-18 • Published 2007-09-18
The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid fragments of the libraries are derived from two or …
Isolating biological modulators from biodiverse gene fragment librariesWO EP US AT AU CA DE DK ES NZ
AU2009251209B2 Wayne Thomas Phylogica Limited
Priority 1999-05-05 • Filed 2009-12-24 • Granted 2012-10-11 • Published 2012-10-11
The present invention provides a method for identifying a modulator or mediator of a biological activity, which activity includes antigenicity and/or immunogenicity, said 5 method comprising the step of: (i) producing a gene fragment expression library derived from defined nucleotide sequence …
Methods of constructing biodiverse gene fragment libraries and biological …US
US7803765B2 Paul Michael Watt Phylogica Limited
Priority 1999-05-05 • Filed 2004-02-20 • Granted 2010-09-28 • Published 2010-09-28
The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid.
Peptide inhibitors of c-jun dimerization and uses thereofWO EP US JP AU CA
EP1793841B1 Paul Michael Watt Phylogica Limited
Priority 2004-08-20 • Filed 2005-08-22 • Granted 2013-04-03 • Published 2013-04-03
An isolated or recombinant peptide or peptide analogue for use in a method for the treatment of ischemia comprising an amino acid sequence selected from the group consisting of: (i) the sequence set forth in SEQ ID NO: 134, or SEQ ID NO: 136, and (ii) a retro-inverted peptide analogue of (i), …
CD40-L Inhibitory PeptidesWO EP US CA
US8802634B2 Paul Michael Watt Phylogica Limited
Priority 2008-07-11 • Filed 2009-07-13 • Granted 2014-08-12 • Published 2014-08-12
The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived …
Compositions and uses thereof for the treatment of woundsWO EP US AU CA
US8946381B2 Mark Fear Phylogica Limited
Priority 2006-09-19 • Filed 2007-02-06 • Granted 2015-02-03 • Published 2015-02-03
We claim: 1. A topical composition comprising (i) an amount of a peptide analog consisting of an amino acid sequence set forth by SEQ ID NO: 104 wherein all amino acids other than glycine are D-amino acids; and (ii) a suitable carrier or excipient. 2. The topical composition according to claim 1
Methods for characterizing interaction sites on target proteinsWO EP US JP
JP6336400B2ワット、ポールフィロジカリミテッドＰｈｙｌｏｇｉｃａＬｉｍｉｔｅｄPriority 2012-02-10 • Filed 2013-02-07 • Granted 2018-06-06 • Published 2018-06-06
A method for characterizing an interaction site on a target protein that can be docked by a small molecule ligand, said target protein modulating a phenotype of a mammalian cell, the method comprising the following steps: (I) a population in which mammalian cells capable of displaying the …
Compositions and uses thereof for the treatment of acute respiratory distress …WO EP US
US8822409B2 Nadia Marian Dorothy Milech Phylogica Limited
Priority 2007-06-20 • Filed 2008-06-20 • Granted 2014-09-02 • Published 2014-09-02
Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS.
An improved genetic screen for interaction interface mappingWO US AU
AU2004243340B2 Marie Bogoyevitch Phylogica Limited
Priority 2003-05-30 • Filed 2004-05-31 • Granted 2009-01-08 • Published 2009-01-08
- The method of claim I wherein unmodified expression of a reporter gene consists of about the same level of expression of said reporter gene in the presence of a native form of the protein of interest and a native form of the other protein. 3. The method of claim 1 or 2 wherein modified …
Peptide modulators of cellular phenotype and bi-nucleic acid fragment libraryWO EP US AU CA DK
AU2005250511B2 Mark Fear Phylogica Limited
Priority 2004-06-03 • Filed 2005-06-03 • Granted 2012-01-19 • Published 2012-01-19
WO 2005/119244 PCT/AU2005/000801 1 Modulators of biochemical characteristics Field of the invention The present invention relates to non-hybrid screening methods for the identification 5 and/or isolation of a peptide that is capable of modulating a phenotype in a cell, tissue or organism.
PROOF OF PROOF FOR PEPTIDESWO EP US AU CA DE
DE69935313T2 Paul M. Claremont WATT Phylogica Ltd., Northbridge
Priority 1998-01-09 • Filed 1999-01-08 • Granted 2007-11-15 • Published 2007-11-15
Method for identifying a peptide, Oligopeptide or polypeptide antagonists of a protein-protein interaction, the two or more interacting proteins in a host cell comprising, the method comprising the steps of: i) Preparation of a Peptide Library in a Cellular Host wherein the transformed cells of …
IMPROVED PROCESS FOR REVERSE N-HYBRID SCREENINGWO EP AT CA DE
DE60120942T2 Richard North Perth HOPKINS Phylogica Ltd., Northbridge
Priority 2000-03-08 • Filed 2001-03-08 • Granted 2007-02-01 • Published 2007-02-01
A method of identifying a peptide that partially or completely inhibits target interaction between two or more binding partners in a host cell but does not inhibit non-target interaction between some but not all of these binding partners, comprising: (I) expression in a cellular host : (A) the …
Improved reverse n-hybrid screening methodAU
AU2001245584B2 Erica Golemis Phylogica Limited
Priority 2000-03-08 • Filed 2001-03-08 • Granted 2007-02-08 • Published 2007-02-08
- A method of identifying a peptide that partially or completely inhibits a target Cinteraction between two or more binding partners in a host cell but does not inhibit a non-target interaction between some but not all of said binding partners, said method comprising: 00 expressing in a cellular …
(20min delay)